The three companies have joined forces to present customers a first of its kind full-service 3D biomanufacturing and in vitro analysis service.

Today, BICO subsidiaries CELLINK, MatTek and Visikol announced the launch of a collaboration combining the expertise of the three companies to establish a contract research organization (CRO) with comprehensive bioprinting services. By forming a joint CRO, CELLINK, MatTek and Visikol have granted their customers access to offerings from all three companies. The partnership furthers the BICO groups’ commitment to its Bio Convergence agenda by identifying synergies in the Bioprinting business area to offer customers solutions trending toward the future of health.

We are very excited to be joining forces with MatTek and Visikol to offer contract research combining our expertise in cell culture, advanced tissue models, 3D bioprinting, imaging, digital pathology and advanced cell culture assays,” says Itedale Namro Redwan, CSO of CELLINK. “We are confident that our joint effort will contribute to minimizing the use of animal models in research.”

The partnership includes MatTek, which brings decades of primary cell isolation experience; CELLINK, which brings a wealth of bioprinting design and biomaterial development expertise; and Visikol: experts in assay development, and in bridging the gap between 3D models and animal studies.

By combining the expertise areas of CELLINK, MatTek and Visikol, we’re able to offer researchers a thorough bioprinting experience,” says Michael Johnson, CEO of Visikol. “I’m very proud of this offering and look forward to what we’re able to achieve.”

The joint CRO will offer custom-designed tissue constructs bioprinted by CELLINK. These constructs can either be delivered to customers’ labs for analysis, or customers can select to have BICO run experiments and deliver a detailed report. Alongside custom bioprinting, this partnership will enable customers to leverage established off-the-shelf 3D tissue models and toxicology services from MatTek, and customers will have access to drug toxicity testing and disease modelling platforms from Visikol’s pre-existing services.

Our complementary technologies and expertise make this partnership with CELLINK and Visikol a natural fit for us,” says Alex Armento, CEO of MatTek. “We’re thrilled to increase our product and service offerings and expand access to more human-relevant testing methods for our customers.”

2021-09-20T09:48:04-05:00

Share This Page, Choose Your Platform!

This website uses cookies to enhance the user experience. Ok